Тройной негативный рак молочной железы (клинико-биологические особенности)
Диссертация
Дальнейшее изучение вопроса привело к еще более интересным результатам. Оказалось, что этот, т.н. молекулярный профиль РМЖ, коррелирует с целым рядом как клинико-лабораторных параметров, так и с чувствительностью к разным режимам лекарственной терапии. Последовало выделение подгрупп РМЖ и среди этих подгрупп наиболее пристальное внимание привлекла группа опухолей, в которых не обнаруживаются… Читать ещё >
Содержание
- СПИСОК СОКРАЩЕНИЙ
- Глава 1. ОБЗОР ЛИТЕРАТУРЫ Тройной негативный рак молочной железы
- Глава 2. ХАРАКТЕРИСТИКА МАТЕРИАЛА И МЕТОДОВ ИССЛЕДОВАНИЯ
- Глава 3. КЛИНИЧЕСКИЕ ОСОБЕННОСТИ ТРОЙНОГО НЕГАТИВНОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
- Глава 4. МОРФОЛОГИЧЕСКАЯ И ИММУНОФЕНОТИПИЧЕСКАЯ ХАРАКТЕРИСТИКА ТРОЙНОГО НЕГАТИВНОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
- Глава 5. СОСТОЯНИЕ ГЕНОВ РЕЦЕПТОРА ЭПИДЕРМАЛЬНОГО ФАКТОРА РОСТА, ТОПОИЗОМЕРАЗЫ 2А И ПТЕН И ХРОМОСОМ 7, 10 И 17 В ТРОЙНОМ НЕГАТИВНОМ РАКЕ МОЛОЧНОЙ ЖЕЛЕЗЫ
Список литературы
- Воскресенский, Д.А. Клинико-морфологические особенности больных раком молочной железы с врожденной мутацией в гене СНЕК2: Автореферат диссертации кандидата медицинских наук: 14.00.14 /Д.А. Воскресенский. -Санкт-Петербург, 2008.-24 с.
- Давыдов, М.И. Заболеваемость злокачественными новообразованиями населения России и стран СНГ в 2007 г./ М. И. Давыдов, Е. М. Аксель // Вестник РОНЦ им. Н. Н. Блохина РАМН. 2009. Т.20, № 3.прил.1). С. 52−90.
- Использование цитоскелетных маркеров для диагностики базальноподобного рака молочной железы / В. Б Дугина, В. Д Ермилова, Г. Ю. Чемерис, Ю. М. Васильев, Т. А. Чипышева // Архив патологии -2010.- Т.72, № 2. С.12−15.
- Кушлинский, Н.Е. Рецепторы эпидермального фактора роста при раке молочной железы: от эксперимента к клинике./ Н. Е. Кушлинский, Е. С. Герштейн // Бюлл. эксп. биол. мед. 1998.- Т. 126, — № 11.- С. 485−496.
- Лавникова, Г. А. Некоторые закономерности лучевого патоморфоза опухолей человека и их практическое использование / Г. А. Лавникова // Вестник Академии медицинских наук СССР. 1976.- № 6, — С. 13−19.
- Летягин В П. В книге Первичные опухоли молочной железы
- В .П. Летягин Москва, 2005, — С. 63−71.
- Хэм, А. Гистология / А. Хэм, Д. Кормак М.: Мир, 1983.- Т. 5 -С. 172−180.
- HER2, ТОР2А, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer/K. Al-Kuraya, H. Novotny, P. Bavi et al. // J. Clin. Pathol.-2007. Vol.60.- P. 768−72.
- Prognostic and predictive factors in breast cancer by immunohistochemical analysis / D.C. Allred, J.M. Harvey, M. Berardo, G.M.Clark // Mod. Pathol. -1998.-Vol. 11. P. 155−168.
- Cadmium malignantly transforms normal human breast epithelial cells into a basal-like phenotype / L. Benbrahim-Tallaa, E.J. Tokar, B.A. Diwan // Environ. Health Perspect.- 2009. -Vol.117, № 12. P. 1847−52.
- How basal are triple-negative breast cancers? / F. Bertucci, P. Finetti, N. Cervera et al. // Int. J. Cancer.- 2008. Vol. 1, № 1.- P.236−40.
- Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 'triple-negative' breast cancers / F.C. Bidard, R. Conforti, T. Boulet et al .// Ann. Oncol.- 2007. Vol.18, № 7.- P. 1285−6.
- PTEN, more than the AKT pathway / C. Blanco-Aparicio, O. Renner, JF. Leal, A. Carnero // Carcinogenesis. -2007.- Vol.28, № 7.- P. 1379−86.
- Bouwman, P Mouse models for BRCA1 associated tumorigenesis: from fundamental insights to preclinical utility / P. Bouwman, J. Jonkers // Cell Cycle. -2008.- Vol.7, № 17. P. 2647−53.
- Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer / B: B. Bryan, S.J. Schnitt, L.C. Collins // Mod. Pathol. -2006.- Vol .19, № 5. P. 617−21.
- Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy / T.A. Buchholz, X. Tu, K.K. Ang et al. // Cancer. -2005.-Vol.15, № 4. -P. 676−81.
- Dysregulated PI3K/Akt/PTEN pathway is a marker of a short disease-free survival in node-negative breast carcinoma/ A. Capodanno, A. Camerini, C. Orlandini et al. // Hum. Pathol. -2009.-Vol. 40, № 10. P. 1408−1722.
- The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes / L.A. Carey, E.C. Dees, L. Sawyer et al. // Clin. Cancer Res. -2007.-Vol. 15, № 8. P. 2329−34.
- Quantitative immunocytochemical profile to predict early outcome of disease in triple-negative breast carcinomas/ C. Charpin, S. Giusiano, V. Secq et al.// Int. J. Oncol. 2009.- Vol.34, № 4. — P. 983−93.
- Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype / M.C. Cheang, D. Voduc, C. Bajdik, et al. // Clin. Cancer Res. 2008.- Vol. 1, № 5. — P. 1368−76.
- Triple-negative breast cancer: MRI features in 29 patients / J.H. Chen, G. Agrawal, B. Feig et al. // Arm. Oncol. 2007.- Vol.8, № 12. — P. 2042−3.
- Magnetic resonance imaging in predicting pathological response of triple negative breast cancer following neoadjuvant chemotherapy/ J.H. Chen, R.S. Mehta, P.M. Carpenter, O. Nalcioglu, M.Y. Su // J. Clin. Oncol. 2007. -Vol. 10, № 35.- P.5667−9.
- Cleator, S. Triple-negative breast cancer: therapeutic options/S.Cleator, W. Heller, R.C. Coombes // Lancet Oncol.- 2007.- Vol.8, № 3.- P. 235−44.
- Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer/ B. Corkery, J. Crown, M. Clynes, N. O’Donovan // Ann. Oncol. 2009.- Vol. 20, № 5.- P. 862−7.
- Increased topoisomerase Ilalpha expression in colorectal cancer is associated with advanced disease and chemotherapeutic resistance via inhibition of apoptosis / A. Coss, M. Tosetto, E.J. Fox et al.//Cancer Lett.-2009.Vol. 18, № 2.-P. 228−38.
- Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile/ D.J. Dabbs, M. Chivukula, G. Carter, R. Bhargava// Mod. Pathol.- 2006.- Vol.19, № 11. -P. 1506−11.
- Dairkee, SH. Expression of basal and luminal epithelium-specific keratins in normal, benign, and malignant breast tissue/ S.H. Dairkee, L. Puett, A.J. Hackett // J. Natl. Cancer Inst.- 1988. Vol. 6, № 9. — P. 691−5
- High-dose chemotherapy for triple negative breast cancer /U.De Giorgi, G. Rosti, L. Frassineti et al. // Ann. Oncol. 2007.- Vol.18, № l.-P. 202−3.
- Pattern of metastatic spread in triple-negative breast cancer/ R. Dent, WM. Hanna, M. Trudeau et al. // Breast Cancer Res. Treat.- 2009.- Vol. 115, № 2.- P.423−8.
- Comparison of topoisomerase-IIalpha gene status between primary breast cancer and corresponding distant metastatic sites / V. Durbecq, A. Di Leo, F. Cardoso et al. // Breast Cancer Res. Treat.- 2003. -Vol.77, № 3. P. 199−204.
- Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype/ S.E. Elsheikh, A.R. Green, E.A. Rakha et al. // Br. J. Cancer.- 2008.- Vol.22, № 2. P.327−34.
- Correlation between CpG methylation profiles and hormone receptor status in breast cancers/ W. Feng, L. Shen, S. Wen et al .// Breast Cancer Res.-2007.- Vol. 9, № 4. -P. R57.
- Genetic and epigenetic alterations in breast cancer: what are the perspectives for clinical practice? / A. Fucito, C. Lucchetti, A. Giordano, G. Romano //Int. J. Biochem. Cell Biol.- 2008.- Vol.40, № 4. P.565−75.
- Recurrence and survival rates among early breast cancer cases with triple negative immunophenotype/ R. Gerson, F. Alban, A. Villalobos, A. Serrano // Gac. Med. Mex.- 2008.- Vol.144, № 1. P .27−34.
- Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children’s Cancer Group 945 cohort / F. Ian, I.F. Pollack, R.L. Hamilton et al. // J. Neurosurg.- 2006. Vol. 105, № 5 (Suppl). -P. 418−24.
- A case of triple negative recurrent breast cancer successfully treated with capecitabine+docetaxel combination chemotherapy/ Y. Hachisuka, Y. Kamei, T. Umeoka et al. // Gan To Kagaku Ryoho.- 2008.- Vol. 35, № 3. P. 475−8.
- Locoregional Relapse and Distant Metastasis in Conservatively. Managed Triple Negative Early-Stage Breast Cancer/ B.G. Haffty, Q. Yang, M. Reiss et al. // J. Clin. Oncol. -2006 .- Vol. 24- P.5652−5657.
- Amplification of TOP2A and HER-2 genes in breast cancers occurring in patients harbouring BRCA1 germline mutations / A.I. Hagen, A.M. Bofin, B. Ytterhus et al. // Acta Oncol.- 2007.- Vol.46, № 2. P. 199−203.
- DNA copy number alterations and expression of relevant genes in triple-negative breast cancer / W. Han, E.M. Jung, J. Cho et al. // Genes Chromosomes Cancer 2008. Vol. 47, № 6. -P. 490−9.
- CD 109 expression in basal-like breast carcinoma / M. Hasegawa, S. Moritani, Y. Murakumo et al. // Pathol. Int.- 2008.- Vol.58, № 5. P. 288−94.
- The molecular portraits of breast tumors are conserved across microarray platforms / Z. Hu, C. Fan, D.S. Oh et al. // B. Genomics 2006.- Vol. 7, — P. 96.
- Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection./ F. Huang, K. Reeves, K. Han et al. // Cancer Res. 2007. Vol. 67. — P. 2226−2238.
- Hurlimann, J. Mononuclear cells infiltrating human mammary carcinomas / J. Hurlimann, P. Saraga // Int. J. Cancer.- 1985.- Vol.15, № 6. -P.753−62.
- Jarvinen, TA. Topoisomerase Ilalpha gene (TOP2A) amplification and deletion in cancer—more common than anticipated/ T.A. Jarvinen, E.T. Liu // Cytopathology. -2003.- Vol.14, № 6. -P. 309−13.
- Impact of PTEN gene knockout in human breast carcinoma MCF-7 cells on activity of JNK pathway / Y. Jin, J.L. Hu, L. Xiao, W. Cui // Ai Zheng. -2008.- Vol. 27, № 12. P. 1239−43.
- Jones, JL. E-cadherin relates to EGFR expression and lymph node metastasis in primary breast carcinoma /J.L. Jones, J.E. Royall, R.A. Walker // Br. J. Cancer. -1996.- Vol.74, № 8. -P.1237−41.
- Kang, SP. Triple negative breast cancer: current understanding of biology and treatment options / S.P. Kang, M. Martel, L.N. Harris // Curr. Opin. Obstet. Gynecol.- 2008.- Vol. 20, № 1.- P. 40−6.
- Kaplan, EL. Nonparametric estimation from incomplete observations / E.L. Kaplan, P. Meier / J. Amer. Statist. Assn. 1958.- Vol.53- P.457−81.
- Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of egfr amplifications despite protein overexpression in invasive breast carcinoma / C. Kersting, N. Tidow, H. Schmidt et al. // Lab. Invest. 2004.-Vol.84,№ 5.-P. 582−7.
- Kobayashi, S. Basal-like subtype of breast cancer: a review of its unique characteristics and their clinical significance / S. Kobayashi, //Breast Cancer. -2008.- Vol.15, № 2. P.153−8.
- Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas / B. Kreike, M. van Kouwenhove, H. Horlings et al. // Breast Cancer Res.- 2007.- Vol. 9, № 5. P. R65.
- Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer / M. Laakso, M. Tanner, J. Nilsson et al. // J. Clin. Cancer Res. 2006. — Vol. 15, № 12. — P. 4185−91.
- LaMarca, HL Hormones and mammary cell fate/ H.L. LaMarca, J.M. Rosen // Endocrinology- 2008.- Vol. 149, № 9. P. 4317−4321.
- The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers / C.O. Leong, N. Vidnovic, M.P. DeYoung et al. // J. Clin. Invest. 2007. Vol. 117, № 5. — P. 1370−80.
- Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas)/ E. Lerma, G. Peiro, T. Ramon et al. // Mod.Pathol. 2007.- Vol. 20, № 11.-P. 1200−7.
- Levin, ER. Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor / E.R. Levin // Mol. Endocrinol. -2003.- Vol. 17, № 3.-P. 309−17.
- Restoring E-cadherin-mediated cell-cell adhesion increases PTEN protein level and stability in human breast carcinoma cells / Z. Li, L. Wang, W. Zhang et al. // 2007.- Vol. 9, № 1.- P. 165−70.
- Topoisomerase II alpha and HER2/neu gene alterations and their correlation in pancreatic ductal adenocarcinomas / Z.Y. Liang, W.Z. Wang, J. Gao et al/ // 2007.- Vol.36, № 2. — P. 102−6.
- Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer / C. Liedtke, C. Mazouni, K.R. Hess et al. // J. Clin. 0ncol.-2008. Vol.10, № 8. — P.'1275−81.
- Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma / C.A. Livasy, G. Karaca, R. Nanda et al. // Mod. Pathol 2006. -Vol.19 — P. 264−271.
- High prevalence of triple-negative tumors in an urban cancer center / M.J. Lund, E.N. Butler, H.L. Bumpers // Cancer. -2008.- Vol.16, № 3. P. 608−615.
- Reduction of E-cadherin expression is associated with non-lobular breast carcinomas of basal-like and triple negative phenotype / B. Mahler-Araujo, K.
- Savage, S. Parry, J.S. Reis-Filho. // J. Clin. Pathol. 2008.- Vol.61, № 5.- P. 615−20.
- Melchor, L. Highway to heaven: mammary gland development and differentiation / L. Melchor, M.J. Smalley // Breast cancer research- 2008.- Vol. 10, № 5.- P. 305.
- Analysis of chromosome aneuploidy in breast carcinoma progression by using fluorescence in situ hybridization. / J. Mendelin, M. Grayson, T. Wallis, D.W. Visscher // Lab. Invest.- 1999, — Vol.79, № 4. P.387−93.
- CCNDl-and ERBB2-gene deregulation and PTEN mutation analyses in invasive lobular carcinoma of the breast/ J. Mercapide, S.Y. Zhang, X. Fan et al. // Mol. Carcinog. 2002.- Vol.35, № 1.- P. 6−12.
- Topoisomerase Ilalpha-positive and BRCA1-negative phenotype: association with favorable response to epirubicin-based regimens for human breast cancers / Y. Miyoshi, M. Kurosumi, J. Kurebayashi et al. // Cancer Lett. -2008.- Vol. 264, № 1.- P. 44−53.
- Simultaneous detection of TOP2A and HER2 gene amplification by multiplex ligation-dependent probe amplification in breast cancer / C.B. Moelans, R.A. de Weger, M.T. van Blokland et al. // Mod. Pathol. 2010. — Vol.23 — P. 162−70.
- Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. / R.E. Mueller, R.K. Parkes, I. Andrulis, F.P. O’Malley // 2004. Vol.39, № 4. P. 288−97.
- Breast cancer subtypes and survival in patients with brain metastases.
- B.H. Nam, S.Y. Kim, H.S. Han et al. // J. Breast Cancer Res. 2008.-Vol. 10, № 1.-P.R20
- Naukkarinen, A. Quantitative immunohistochemical analysis of mononuclear infiltrates in breast carcinomas correlation with tumour differentiation. / A. Naukkarinen, K.J. Syrjanen .// J. Pathol. -1990.- V0I. I6O-P. 217−222.
- Germline mutations and variants in the succinate dehydrogenase genes in Cowden and Cowden-like syndromes / Y. Ni, K.M. Zbuk, T. Sadler et al. // Am. J. Hum. Genet.- 2008.- Vol.83, № 2. P. 261−8.
- Epidermal growth factor receptor (EGFr) — results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup / S. Nicholson, J. Richard, C. Sainsbury et al. // Br. J. Cancer. -1991.- Vol. 63, № l.-P. 146−50.
- The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D/K.V. Nielsen, B. Ejlertsen, S. M0ller et al .// Acta Oncol.- 2008.- Vol.47, № 4. P. 725−34.
- Aberrations of ERBB2 and TOP2A Genes in Breast Cancer / KV. Nielsen, S. Miiller, S. M0ller et al. // Mol. Oncol.-2010. Vol.4, № 2.-P. 161−168.
- Nishimura, R. Is triple negative a prognostic factor in breast cancer? / R. Nishimura, N. Arima // Breast Cancer.- 2008. Vol.29, № 4. P. 303−8.
- EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer / H. Nogi, T. Kobayashi, M. Suzuki et al. // Oncol. Rep.- 2009.- Vol.21, № 2.- P.413−7.
- Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy / F.P. O’Malley, S. Chia, D. Tu et al. // J. Natl. Cancer Inst.2009.- Vol.6, № 9. P. 644−50.
- Prognostic Value of Triple-Negative Phenotype at the Time of Locally Recurrent, Conservatively Treated Breast Cancer / R.R. Parikh, D. Housman, Q. Yang et al. // Int. J. Radiat. Oncol. Biol. Phys. 2008.- Vol. 15, № 4. — P. 105 663.
- Outcomes in young women with breast cancer of triple-negative phenotype: the prognostic significance of CK19 expression / R.R. Parikh, Q. Yang S.A. Higgins, B.G. Haffty // Int. J. Radiat. Oncol. Biol. Phys. 2008.- Vol. 1, № 1.-P. 35−42.
- Topoisomerase II-alpha gene deletion is not frequent as its amplification in breast cancer / K. Park, S. Han, G.H. Gwak et al. // Breast Cancer Res. Treat. 2006.- Vol.98, № 3. — P. 337−42.
- Pechoux, C. Human mammary luminal epithelial cells contain progenitors to myoepithelial cells / C. Pechoux, T. Gudjonsson, L. RonnovJessen // Dev. Biol.- 1999.- Vol. 206-P. 88−99.
- Molecular portraits of human breast tumours / C.M. Perou, T. S0rlie, M.B. Eisen et al. // Nature. 2000.- Vol.406, № 6797. — P. 747−52.
- Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women / A.I. Phipps, K.E. Malone, P.L. Porter et al. // Cancer Epidemiol. Biomarkers Prev. 2008.- Vol.17, № 8. P. 2078−86.
- Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer / A.I. Phipps, K.E. Malone, P.L.Porter, J.R. Daling, C.I. Li // Cancer.- 2008.- Vol.25, № 7.-P. 1521−6.
- Piekarski, JH. Clinical significance of CK5/6 and PTEN protein expression in patients with bilateral breast carcinoma / J.H. Piekarski, W. Biernat // Histopathology.- 2006.- Vol.49, № 3.- P. 248−55.
- Developmental Tumorigenesis: NCAM as a putative marker for the malignant renal stem/progenitor cell population / N. Pode-Shakked, S. Metsuyanim, E. Rom-Gross et al. // J. Cell Mol. Med.- 2009.- Vol.13, № 8B. -P. 1792−808.
- Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis / T.C. Putti, D.M. El Rehim, E.A. Rakha et al. //Mod. Pathol.-2005.-Vol. 18, — P. 26−35.
- Prognostic markers in triple-negative breast cancer / E.A. Rakha, M.E. El-Sayed, A.R.Green et al.//Cancer.-2007.-Vol.1, № 1.-P. 25−32.
- Reis-Filho, JS. Triple negative tumours: a critical review/ J.S. Reis-Filho, A.N. Tutt // Histopathology. 2008.- Vol.52, № 1. — P. 108−18.
- Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer / A. Rody, T. Karn, E. Ruckhaberle et al. // Breast Cancer Res.Treat. 2009. Vol. 113, № 3. — P. 457−66.
- Sarkar, K. Myoepithelial cells in carcinoma of human breast /K.Sarkar, E. Kallenbach // Am. J. Pathol. 1966.- Vol.49, № 2. — P. 301−7.
- Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer / M. Sasa, Y. Bando, M. Takahashi et al.// J. Surg. Oncol.- 2008.- Vol.1, № 1. P.30−4.
- Molecular subgroups of small (pTl) breast carcinomas belonging exclusively to the ductal infiltrating variety / J. Schneider, A. Tejerina, C. Perea et al. // Cancer Genomics Proteomics.- 2007. Vol.4, № 6.- P. 399−402.
- Generation of a functional mammary gland from a single stem cell / M. Shackleton, F. Vaillant, K.J. Simpson et al. // Nature.- 2006.-Vol.5, № 7072.-P.84−88.
- The basal-like mammary carcinomas induced by Brcal or Bardl inactivation implicate the BRCA1/BARD1 heterodimer in tumor suppression / R. Shakya, M. Szabolcs, E. McCarthy et al. // Proc. Natl. Acad .Sci. U S A.- 2008. Vol.13, № 19.-P. 7040−5.
- Dual immunocytochemical analysis of oestrogen and epidermal growth factor receptors in human breast cancer / A.K. Sharma, K. Horgan, A. DouglasJones et al. // Br. J. Cancer. 1994.- Vol.69, № 6.- P. 1032−7.
- Frequent overexpression of epidermal growth factor receptor (EGFR) in mammary high grade ductal carcinomas with myoepithelial differentiation / T. Shien, T. Tashiro, M. Omatsu et al. // J. Clin. Pathol. -2005. Vol.58, № 12.-P. 1299−304.
- Shiu, KK. Development of therapeutic approaches to 'triple negative' phenotype breast cancer. / K.K. Shiu, D.S. Tan, J.S. Reis-Filho // Expert Opinion Ther. Targets.- 2008. Vol.12, № 9.- P. 1123−37.
- HER-2 and TOP2A coamplification in urinary bladder cancer /R. Simon, R. Atefy, U. Wagner et al. // Int. J. Cancer. -2003.- Vol.10, № 5. P. — 764−72.
- PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer / K. Sircar, M. Yoshimoto, F.A. Monzon et al. // J. Pathol.- 2009, — Vol.218, № 4.- P. 505−13.
- Platinium -based chemotherapy in triple-negative breast cancer / B. Sirohi, M. Arnedos, S. Popat et al. // Ann. Oncol. 2008. — Vol.19, № 11, — P. 1847−52.
- Siziopikou, KP. The basal subtypes of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies / K.P. Siziopikou, M. Cobleigh // Breast.- 2007.- Vol.16, № 1.- P. 104−7.
- Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. / J.C. Soria, H.Y. Lee, J.I. Lee et al. // Clin. Cancer Res.- 2002.- Vol.8, № 5.- P. 1178−84.
- Breast cancer classification and prognosis based on gene expression profiles from a population-based study / C. Sotiriou, S.Y. Neo, L.M. McShane et al. // Proc. Natl. Acad. Sci. U S A. -2003.- Vol. 2, № 18.- P.- 10 393−8.
- Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer / J.A. Sparano, L.J. Goldstein, B.H. Childs et al. // Clin. Cancer Res. 2009.- Vol.15, № 24/- P.-7693−7700.
- Sternlicht, M. D. Key stages in mammary gland development: The cues that regulate ductal branching morphogenesis / M.D. Sternlicht // Breast cancer research. 2006.- Vol.8- P. 201.
- Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients / D.S. Tan, .C. Marchio, R.L. Jones et al. // Breast Cancer Res. Treat. 2008. — Vol.111, № 1.- P.- 27−44.
- Primary breast cancer phenotypes associated with propensity for central nervous system metastases / Y.L. Tham, K. Sexton, R. Kramer, S. Hilsenbeck, R. Elledge // Cancer.- 2006.- Vol.15, № 4. P. 696−704.
- Use of immunohistochemical markers can refine prognosis in triple negative breast cancer / M. Tischkowitz, J.C. Brunet, R.L. Begin et al. //BMC Cancer. -2007. Vol. 7. — P. 134.
- Low incidence of methylation of the promoter region of the FANCF gene in Japanese primary breast cancer /E.Tokunaga, S. Okada, H. Kitao et al. // Breast Cancer.- 2009.- Vol.4, № 8.- P. 239−315.
- Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers / T. Toyama, H. Yamashita, N. Kondo et al. // BMC Cancer.-2008.- Vol. 25, № 8. P. 309.
- Myoepithelial differentiation in high-grade invasive ductal carcinomas with large central acellular zones / H. Tsuda, T. Takarabe, T. Hasegawa et al. // Hum Pathol.- 1999.- Vol. 30.- P. l 134−1139.
- Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status / R. Tubbs, W.E. Barlow, G.T. Budd et al. // J. Clin. Oncol.- 2009. Vol.20, № 24.-P. 3881−6.
- Turner, N. Hallmarks of" BCRAness" in sporadic cancers / N. Turner, N. Tutt, A. Ashworth //Nat. Res. Cancer-2004.-Vol. 4.-P. 814−81.
- Invasive ductal carcinoma of the breast with the «triple-negative» phenotype: prognostic implications of EGFR immunoreactivity / G. Viale, N. Rotmensz, P. Maisonneuve et al. // Breast Cancer Res. Treat. 2009.- Vol.116, № 2, P. 317−28.
- Waite, KA. Protean PTEN: form and function / K.A. Waite, C. Eng // Am. J. Hum. Genet. 2002.- Vol.70, № 4 .- P. 829−44.
- Increased expression of osteopontin in patients with triple-negative breast cancer / X. Wang, L. Chao, G. Ma et al .// Eur. J. Clin. Invest.- 2008.-Vol. 38, № 6.- P. 438−46.
- Wennmalm, K. The expression signature of in vitro senescence resembles mouse but not human aging / K. Wennmalm, C. Wahlestedt, O. Larsson // Genome Biol. 2005. — Vol.6, № 13.- P. R109.
- Wilcoxon, F. Individual comparisons by ranking methods / F. Wilcoxon //Biometrics.- 1945.Vol.l. P.80−83.
- Measurement of PTEN expression using tissue microarrays to determine a race-specific prognostic marker in breast cancer / J.L. Winter, B.L. Stackhouse ,
- G.B. Russell, T.E. Kute // Arch. Pathol.Lab. Med.- 2007, — Vol.131, № 5. P. 76 772.
- To KF. TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance / N. Wong, W. Yeo, W.L. Wong et al. // Int. J. Cancer.- 2009.- Vol.1, № 3.- P. 644−52.
- Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women / W.T. Yang, M. Dryden, K. Broglio et al. // Breast Cancer Res. Treat. 2007.- Vol.17, № 3.- P. 405−10.
- Yang, XF. Clinicopathological significance of PTEN and Caspase-3 expressions in breast cancer / X.F. Yang, Y. Xin, L.L. Mao // Chin. Med. Sci. J.-2008, — Vol.23, № 2,-P. 95−102.
- Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event / I.T. Yeh, M.A. Martin, R.S. Robetorye et al.// Mod. Pathol. 2009.- Vol.22, № 9. — P. 1169−75.
- Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients / W.J. Yin, J.S. Lu, G.H. Di et al. // Breast Cancer Res. Treat.-2009. Vol.115, № 2.- P. 325−33.
- Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intraepithelial neoplasias / M. Yoshimoto, J.C. Cutz, P.A. Nuin et al. // 2006. -Vol.169, № 2-P. 128−37.
- Clinical Characteristics and Prognosis of Triple-negative Breast Cancer: A Report of 305 Cases / Z.Y. Yuan, S.S. Wang, Y. Gao et al.// Ai Zheng.-2008. Vol.27, № 6.- P. 561−5.
- Zangen, R. DeltaNp63alpha levels correlate with clinical tumor response to cisplatin. /R. Zangen, E. Ratovitski, D. Sidransky // Cell Cycle. -2005.-Vol.4, № 10.- P. 1313−5.
- Epigenetic PTEN silencing in malignant melanomas without PTEN mutation / X.P. Zhou, O. Gimm, H. Hampel, et al. // Am. J. Pathol.- 2000.-Vol.157.-P. 1123−1128.